667. New Antiretroviral Agents
Session: Symposium: HIV State-of-the-Art
Friday, October 19, 2012: 10:30 AM
Room: SDCC 28 ABCDE
Despite the current availability of 26 FDA-approved antiretroviral drugs, we continue to need newer drugs that are more potent, less toxic, more tolerable, more convenient, and/or have improved virologic activity against drug-resistant viral strains.  The current antiretroviral agent pipeline is full, with new investigational nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors (EIs), integrase inhibitors (IIs), and other compounds with new mechanisms of action.  Investigational agents that have unique properties and those that are the farthest along in clinical development will be reviewed.
Roy M. Gulick, MD, FIDSA, Weill Cornell Medical College, New York, NY

Dr. Gulick is Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York City. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral treatment and prevention strategies and assess antiretroviral drugs with new mechanisms of action. He currently serves as Principal Investigator of the Cornell HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), sponsored by the National Institutes of Health. He also serves as a Board Member of the International Antiviral Society-USA, and as a member of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services. He previously served as Chairman of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and as Co-Chairman of the Forum for Collaborative HIV Research. He is a member of the American Society of Clinical Investigation, the Infectious Diseases Society of America, and the International AIDS Society and has presented at national and international meetings and published widely in the field of HIV/AIDS.



See more of: HIV State-of-the-Art
See more of: Symposium
Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.